{"id":32782,"date":"2025-05-28T11:49:06","date_gmt":"2025-05-28T15:49:06","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=32782"},"modified":"2026-04-25T14:54:24","modified_gmt":"2026-04-25T18:54:24","slug":"how-to-create-a-robust-generic-drug-quality-management-system","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/how-to-create-a-robust-generic-drug-quality-management-system\/","title":{"rendered":"Generic Drug QMS: The Complete Technical, Regulatory, and IP Strategy Guide"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Quality failures in generic drug manufacturing are not a compliance inconvenience. They are a market-exit event. Between 2022 and 2024, 42% of newly reported U.S. drug shortages traced back to manufacturing quality problems and production delays, according to FDA data presented at the Generic Drugs Forum. The generic industry saved the U.S. healthcare system an estimated $445 billion in 2024 alone, yet the same cost-compression logic that makes generics indispensable to payers also produces the financial fragility that leaves hospital formularies empty. A Quality Management System (QMS) built to the minimum current Good Manufacturing Practice (cGMP) floor is no longer a viable competitive posture. The manufacturers that survive the coming consolidation cycle will be those that treat quality infrastructure as a balance-sheet asset rather than a regulatory obligation.<\/p>\n\n\n\n

This guide covers every layer of that infrastructure: the ICH and FDA regulatory architecture, Quality by Design (QbD) implementation from first-principles, the FDA’s Quality Management Maturity (QMM) program and its strategic implications, data integrity and 21 CFR Part 11 compliance, supplier qualification at scale, CAPA system design, process analytical technology (PAT) deployment, and the IP dimensions that QMS documentation creates or destroys.<\/p>\n\n\n\n

\n\n\n\n

The Business Case: Why a Weak QMS Destroys More Value Than a Recall<\/strong><\/h2>\n\n\n\n

Visible quality failures, Warning Letters, import alerts, and consent decrees, carry obvious costs. Less visible is the compounding opportunity cost that accumulates before regulators arrive.<\/p>\n\n\n\n

The IQVIA Institute’s 2024 analysis of ANDA approvals and drug shortages found that 37% of all generics approved between 2013 and Q1 2024 had not launched commercially. For drugs already in active shortage, 62% had at least one FDA-approved generic alternative, and 84% of those shortage drugs had at least one approved-but-unlaunched product sitting idle. The only commercially rational explanation for not launching an approved product is that projected returns are negative, often because per-unit quality costs in a sterile injectable or narrow therapeutic index oral solid have consumed the margin entirely.<\/p>\n\n\n\n

Manufacturing-quality problems were linked to 62% of all drugs that went into shortage between 2013 and 2017. That figure moderated to approximately 40% by 2022-2023, but the structural problem remains: cGMP compliance is binary in FDA’s enforcement calculus, while QMM is continuous. The market has historically failed to price the difference, which is precisely why FDA launched the QMM program.<\/p>\n\n\n\n

The U.S. generic drug market was valued at roughly $95.87 billion in 2024, with projections to $131.8 billion by 2033. Price erosion is structural. The only durable margin lever available to generic manufacturers, absent a first-to-file 180-day exclusivity position, is cost efficiency and quality throughput. A QMS that minimizes batch failures, shortens deviation-to-closure cycle times, and reduces Complete Response Letter (CRL) rounds directly converts into launch timing advantage and cost-per-unit.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

The business case for a mature QMS rests on four numbers: the $445 billion in annual healthcare savings that generics produce (creating enormous political and payer pressure to keep prices low); the 42% of drug shortages driven by quality and manufacturing failures (linking QMS weakness directly to supply risk); the 37% of approved generics that never reach market (where quality costs are often the decisive factor); and the FDA’s own finding that manufacturers with mature quality systems detect problems earlier, reducing the remediation costs that inflate cost-of-goods.<\/p>\n\n\n\n

Investment Strategy<\/strong><\/p>\n\n\n\n

Portfolio managers evaluating generic drug manufacturers should weight QMS maturity as a proxy for regulatory tail risk. A manufacturer with an active Warning Letter, an FDA Import Alert under 21 CFR 314.81(b)(2), or more than two CRL cycles on a major ANDA represents a significantly higher probability of supply disruption than financials alone indicate. The QMM assessment score, once FDA formalizes a public-facing rating system, will become a procurement and M&A diligence datapoint of the first order.<\/p>\n\n\n\n

\n\n\n\n

The Regulatory Architecture: ICH Guidelines, cGMP, and the QMM Program<\/strong><\/h2>\n\n\n\n

ICH Q8, Q9, Q10, and Q12: The Lifecycle Framework<\/strong><\/h3>\n\n\n\n

The ICH quality guidelines do not operate independently. Q8(R2) (Pharmaceutical Development), Q9(R1) (Quality Risk Management), Q10 (Pharmaceutical Quality System), and Q12 (Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management) form a linked framework that FDA incorporated into its regulatory expectations beginning in the mid-2000s.<\/p>\n\n\n\n

ICH Q10 defines four elements of a Pharmaceutical Quality System relevant to generic manufacturers: process performance and product quality monitoring, corrective action and preventive action (CAPA), change management, and management review. Each element has direct analog in cGMP requirements under 21 CFR Part 211, but ICH Q10 goes further by requiring that manufacturers demonstrate continuous improvement rather than static compliance. The distinction matters: an inspection under 21 CFR Part 211 evaluates whether the floor was met at a point in time; a QMM assessment evaluates whether the organization is structurally capable of detecting and correcting its own deficiencies before FDA arrives.<\/p>\n\n\n\n

ICH Q12 (finalized by FDA in May 2021) introduced the concept of Established Conditions (ECs), the subset of manufacturing parameters whose change requires a regulatory filing. Manufacturers that have correctly identified their ECs through QbD-driven development can make post-approval manufacturing changes through lower-burden annual reporting or changes-being-effected (CBE) supplements rather than prior-approval supplements (PAS). This directly accelerates process optimization cycles and reduces the regulatory overhead of continuous improvement, which is the mechanism that turns QMM investment into margin recovery.<\/p>\n\n\n\n

cGMP Under 21 CFR Parts 210 and 211: The Compliance Baseline<\/strong><\/h3>\n\n\n\n

21 CFR Parts 210 and 211 establish minimum standards for methods, facilities, and controls used in manufacturing, processing, packing, and holding drug products. For generic manufacturers, the critical sections are: Part 211 Subpart E (Control of Components and Drug Product Containers and Closures), Subpart F (Production and Process Controls), Subpart I (Laboratory Controls), and Subpart J (Records and Reports).<\/p>\n\n\n\n

The most common Warning Letter citations for generic manufacturers cluster in three areas: inadequate laboratory investigations (21 CFR 211.192), failure to thoroughly investigate unexplained discrepancies (21 CFR 211.192), and failure to establish written procedures for production and process controls (21 CFR 211.100). All three reflect systemic QMS design failures rather than isolated operator errors.<\/p>\n\n\n\n

Data integrity violations, specifically failures under 21 CFR Part 11 for electronic records and signatures, have risen sharply as a Warning Letter category since 2015. FDA’s expectations for audit trails, access controls, and the prohibition on back-dating or deleting raw data are non-negotiable and have resulted in multiple consent decrees against both domestic and Indian API manufacturers.<\/p>\n\n\n\n

The FDA Quality Management Maturity Program: Strategic Implications<\/strong><\/h3>\n\n\n\n

FDA’s QMM program represents the most consequential regulatory policy shift for generic manufacturers since GDUFA I in 2012. The program’s genesis traces to a 2019 FDA Drug Shortage Task Force finding that the market fails to recognize or reward manufacturers with mature quality systems. CGMP compliance is binary; good manufacturers and mediocre manufacturers receive the same regulatory status if neither has a current enforcement action. The Task Force concluded that this market failure was a structural driver of drug shortages.<\/p>\n\n\n\n

CDER launched QMM pilot programs from 2020 to 2022, covering both finished dosage form (FDF) manufacturers and foreign API facilities. Those pilots used third-party assessors to evaluate facilities against rubrics covering management commitment, operational excellence, supply chain resilience, and quality culture. Nine additional establishments participated in the 2024 QMM Prototype Assessment Protocol Evaluation Program. The rubric formally scored five practice areas: management commitment to quality, business continuity, technical excellence, advanced pharmaceutical quality system, and employee empowerment and engagement.<\/p>\n\n\n\n

The 2024 cohort data, presented at the Generic Drugs Forum, showed a consistent pattern: high scores for management commitment and employee engagement (many facilities scored 4 of 5), and markedly lower scores in technical excellence and advanced quality systems. This gap maps directly onto the ICH Q12 capability gap described above: manufacturers have built quality cultures but have not systematically connected quality culture to manufacturing science and post-approval change management.<\/p>\n\n\n\n

FDA published the 2025 QMM Prototype Assessment Protocol in April 2025, accepting participation requests through April 13, 2026, with up to nine additional establishments. A third-year iteration was announced in February 2026 via Federal Register. The program remains voluntary and explicitly cannot be used to determine CGMP compliance. However, FDA’s white paper, ‘Quality Management Initiatives in the Pharmaceutical Industry: An Economic Perspective,’ argues that strategic QMM investment produces measurable economic returns for manufacturers and public health. Once FDA formalizes a public-facing rating system, as it has signaled intent to do, QMM scores will influence hospital and GPO procurement decisions, federal contract awards, and ANDA review prioritization in shortage categories.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

The QMM program moves FDA’s quality policy from binary compliance to continuous differentiation. Manufacturers currently scoring in the bottom half of the QMM rubric on technical excellence face a multi-year capability build to reach competitive parity. The time to begin that build is before a public rating system exists, not after competitors have established a score differential that procurement officers can cite.<\/p>\n\n\n\n

Investment Strategy<\/strong><\/p>\n\n\n\n

Generic manufacturers with QMM participation on record and documented practice-area improvement plans will command a regulatory risk premium in M&A valuations and CDMO contract negotiations. The QMM assessment report that participating facilities receive, with practice-area scores and actionable improvement opportunities, is a documented audit trail of management commitment that acquirers and institutional lenders can value. Facilities without participation in the program by the time ratings are formalized will face procurement disadvantages at both the GPO level and in federal emergency stockpile contracts.<\/p>\n\n\n\n

\n\n\n\n

Quality by Design: The Technical Architecture<\/strong><\/h2>\n\n\n\n

Defining the Quality Target Product Profile<\/strong><\/h3>\n\n\n\n

QbD begins with the Quality Target Product Profile (QTPP), the prospective summary of the intended quality characteristics of a drug product that ideally will be achieved to ensure the desired quality, safety, and efficacy. For a generic manufacturer filing an ANDA, the QTPP is constrained by the reference listed drug (RLD): the approved dosage form, route of administration, dosage strength, container closure system, and release mechanism define the boundaries within which the generic must demonstrate pharmaceutical equivalence and bioequivalence.<\/p>\n\n\n\n

The practical starting point for QTPP development is a structured analysis of the RLD’s labeling, the FDA’s product-specific guidance (PSG), and any relevant bioequivalence guidance. PSGs, which FDA has issued for hundreds of complex formulations under GDUFA III, specify the recommended in vitro and in vivo study designs, acceptable bioequivalence standards, and formulation constraints. A QTPP that diverges from PSG recommendations without scientific justification will generate a CRL at the CMC review stage.<\/p>\n\n\n\n

From the QTPP, the development team identifies critical quality attributes (CQAs): physical, chemical, biological, or microbiological properties that must be within an appropriate limit, range, or distribution to ensure product quality. For an immediate-release oral solid, the CQA list typically includes assay, related substances (degradation products), dissolution, content uniformity, and physical attributes such as hardness and friability. For an ophthalmic solution, sterility, osmolality, pH, preservative content, and particulate matter are CQAs. Each CQA maps to one or more critical material attributes (CMAs) of drug substance or excipients, and one or more critical process parameters (CPPs) of the manufacturing process.<\/p>\n\n\n\n

Design Space, Control Strategy, and the ICH Q8 Filing<\/strong><\/h3>\n\n\n\n

Design space, as defined in ICH Q8(R2), is the multidimensional combination and interaction of input variables and process parameters that have been demonstrated to provide assurance of quality. Working within the design space is not considered a change; moving outside requires a regulatory submission. For generic manufacturers, establishing a meaningful design space requires Design of Experiments (DoE) studies that map the response surface across CMA and CPP ranges. A two-level full factorial design handles up to five factors without interaction aliasing; more complex formulations require central composite designs (CCD) or Box-Behnken designs.<\/p>\n\n\n\n

The control strategy derived from QbD development sits above design space in the ANDA. It encompasses specifications for drug substance, excipients, in-process materials, and drug product; process controls at each manufacturing step; and enhanced testing where the manufacturing process alone cannot provide sufficient assurance. A risk-based control strategy documented through a quality risk management (QRM) tool such as Failure Mode and Effects Analysis (FMEA) or fault tree analysis (FTA) satisfies both ICH Q9 requirements and FDA’s expectation that manufacturers can demonstrate which parameters actually drive product quality and why.<\/p>\n\n\n\n

Process Analytical Technology: Real-Time Quality Assurance<\/strong><\/h3>\n\n\n\n

PAT, as defined in FDA’s 2004 guidance framework, is a system for designing, analyzing, and controlling pharmaceutical manufacturing processes through timely measurements of critical quality and performance attributes of raw and in-process materials and processes, with the goal of ensuring final product quality. For generic manufacturers, PAT deployment concentrated initially in granulation endpoint detection (near-infrared spectroscopy for blend uniformity), tablet compression (force-displacement monitoring for hardness and weight), and coating (in-line spray rate and bed temperature monitoring).<\/p>\n\n\n\n

The current generation of PAT deployment extends into continuous manufacturing (CM) lines, where NIR, Raman, and UV-Vis probes monitor CQAs in real time across linked unit operations. FDA has approved CM ANDAs for multiple solid oral dosage forms, and the agency has signaled through its Pharmaceutical Quality for the 21st Century initiative that CM represents a preferred manufacturing paradigm for supply chain resilience. The regulatory pathway for CM in an ANDA involves filing a manufacturing description that includes the CM control strategy, real-time release testing (RTRT) protocols that use in-process PAT data to replace or supplement end-product testing, and a process qualification protocol demonstrating steady-state operation.<\/p>\n\n\n\n

Batch failure rates in CM systems are structurally lower than batch manufacturing because the control loop operates at the unit operation level, correcting deviations before they propagate through an entire batch. A single granulation failure in a batch system wastes the entire batch; a comparable deviation in a CM system triggers a divert mechanism that removes non-conforming material from the flow, with the conforming remainder released. The economic case for CM investment in high-volume generic manufacturing is strong, but the upfront validation burden is significant. FDA’s CM guidance, published in 2019, provides the validation framework.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

QbD’s technical value to generic manufacturers is not theoretical. A development program that correctly identifies CQAs, builds a statistically characterized design space, and implements a risk-based control strategy produces three direct regulatory benefits: a lower CRL rate on first cycle review, the ability to make post-approval manufacturing changes through lower-burden pathways under ICH Q12, and a documented scientific rationale that supports GMP inspection defense. The average cost of a single CRL round, including response preparation, resubmission, and review cycle time, runs to millions of dollars in delayed revenue. A QbD-designed CMC package that avoids one CRL cycle more than pays for the development investment.<\/p>\n\n\n\n

\n\n\n\n

QMS Architecture: Document Control, CAPA, and Change Management<\/strong><\/h2>\n\n\n\n

Document Control: The Compliance Backbone<\/strong><\/h3>\n\n\n\n

A generic drug QMS rests on a document control system that maintains current, controlled, and version-tracked copies of every quality-relevant record: SOPs, batch manufacturing records (BMRs), batch packaging records (BPRs), master validation protocols, analytical methods, and product specifications. FDA’s expectation under 21 CFR 211.186 is that master production and control records exist for each drug product, each drug product strength, and each batch size. Deviation from master records requires documented and approved deviation management procedures.<\/p>\n\n\n\n

Electronic document management systems (eDMS) have replaced paper-based systems at all scale-competitive generic manufacturers. The regulatory requirements for eDMS derive from 21 CFR Part 11 (electronic records and electronic signatures), which mandates audit trails, access controls, and the ability to generate accurate and complete copies of records for FDA inspection. A Part 11-compliant eDMS must: maintain audit trails that capture the date and time of operator entries, changes, and deletions; require that electronic signatures link the signature to the record; and prevent modification of records after they are finalized without generating an audit trail entry.<\/p>\n\n\n\n

Common Part 11 deficiencies cited in Warning Letters include: shared login credentials (violating the unique user access requirement), inadequate audit trail review (the requirement to review audit trails at least as frequently as the records they accompany), and failure to validate the eDMS itself under 21 CFR Part 11 validation standards. System validation under GAMP 5 (Good Automated Manufacturing Practice), which classifies software by category from 3 (commercial off-the-shelf with configurable options) to 5 (custom software), provides the standard validation framework.<\/p>\n\n\n\n

CAPA System Design: Closing the Loop<\/strong><\/h3>\n\n\n\n

The Corrective and Preventive Action system is the mechanism by which a QMS converts quality events into manufacturing improvement. A CAPA that closes on paper without demonstrating effectiveness is the regulatory definition of a systemic deficiency. FDA’s 2011 guidance on process validation specifies that manufacturers use statistical process control (SPC) and process capability indices (Cp, Cpk) to evaluate process performance data during the continued process verification (CPV) stage. A CAPA triggered by a process trend, before a batch failure occurs, is the operational expression of QMM.<\/p>\n\n\n\n

Effective CAPA design requires four elements: an accurate root cause analysis (RCA) tool matched to the problem type; corrective actions that address root cause rather than symptom; preventive actions that extend the correction across analogous processes or products in the portfolio; and an effectiveness check protocol with defined acceptance criteria and a defined time window for assessment. RCA tools appropriate for different problem types include Ishikawa (fishbone) diagrams for complex multi-factor manufacturing deviations, 5-Why analysis for equipment-related failures, and fault tree analysis for sterile manufacturing contamination investigations. Selecting the wrong tool produces a superficial causal chain that generates a repeat CAPA.<\/p>\n\n\n\n

CAPA cycle time, the time from event opening to effectiveness check completion, is a direct QMM indicator. A median CAPA cycle time exceeding 90 days for non-critical deviations or 30 days for critical deviations signals a QMS that cannot self-correct at the speed manufacturing demands. FDA investigators track CAPA aging as a proxy for organizational quality culture, and a pattern of overdue CAPAs almost always appears in Warning Letter observations as evidence that the CAPA system is not effective.<\/p>\n\n\n\n

Change Management: Post-Approval Variations and the ICH Q12 Opportunity<\/strong><\/h3>\n\n\n\n

Post-approval change management sits at the intersection of QMS capability and IP strategy. Every manufacturing change at an FDA-approved site requires classification: whether it is a prior approval supplement (PAS), a changes-being-effected-in-30-days (CBE-30) supplement, a changes-being-effected (CBE) supplement, or an annual report (AR). The classification depends on the potential for the change to have an adverse effect on the identity, strength, quality, purity, or potency of the drug product.<\/p>\n\n\n\n

ICH Q12 introduced two tools to reduce the regulatory burden of post-approval change management for manufacturers that invested in QbD development. Established Conditions (ECs) define the approved state; changes to ECs require a PAS. Post-Approval Change Management Protocols (PACMPs) allow manufacturers to pre-specify a change and its associated studies in a regulatory submission, enabling the subsequent implementation of that change through a lower-burden supplement after the PACAMP is approved. For generic manufacturers operating high-volume lines with continuous process improvement programs, the PACMP mechanism converts what would have been multiple PAS submissions into a single pre-approval package followed by CBE or AR implementations.<\/p>\n\n\n\n

The IP implication of post-approval change management is underappreciated. When a generic manufacturer develops a novel process improvement, whether a proprietary crystallization method for an API, a continuous manufacturing configuration, or a novel formulation approach that improves bioequivalence metrics, that improvement may be patentable as a method of manufacture or formulation patent. The QMS documentation of that development, including DoE data, process characterization studies, and CMC change supplements, constitutes the evidentiary record for a patent application. Generic manufacturers that treat QMS documentation as a liability management tool rather than a potential IP asset leave significant value on the table.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

The three systems, document control, CAPA, and change management, are only as strong as the data they generate. A document control system that stores records without enabling trend analysis produces compliance without intelligence. A CAPA system that closes events without tracking recurrence produces documentation without learning. A change management program that routes every modification through PAS regardless of its actual regulatory impact produces regulatory burden without safety benefit. All three failures are addressable through process redesign before FDA identifies them.<\/p>\n\n\n\n

\n\n\n\n

Supplier Qualification and Supply Chain Risk Management<\/strong><\/h2>\n\n\n\n

Risk-Based Supplier Assessment<\/strong><\/h3>\n\n\n\n

A generic drug QMS cannot be evaluated independently of its supplier qualification program. APIs, excipients, primary packaging materials, and secondary packaging materials each carry quality, identity, and traceability requirements under 21 CFR Part 211. The API supplier qualification requirement is particularly stringent: 21 CFR 211.84 requires identity testing of each lot of components, and ICH Q7 (Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients) establishes GMP standards for API manufacturers that finished-dose manufacturers are expected to verify through qualification and audit.<\/p>\n\n\n\n

Risk-based supplier assessment classifies suppliers by risk tier based on three factors: the criticality of the supplied material to final product quality (a CMA), the supplier’s demonstrated quality history, and the availability of alternative qualified sources. Tier-1 suppliers, those providing materials with direct CQA impact and limited alternative sourcing, require full on-site qualification audits on a defined cycle (typically every two to three years), real-time quality data sharing, and joint deviation investigation protocols. Tier-2 suppliers for non-critical materials may be managed through questionnaire-based desktop audits and certificate of analysis (CoA) verification programs.<\/p>\n\n\n\n

API supply chain geography carries regulatory risk that supplier scorecards must capture. As of August 2024, only 24% of API manufacturing facilities for U.S.-marketed drugs were located in the United States. The concentration of API manufacturing in China and India creates regulatory exposure when FDA issues Import Alerts or when geopolitical disruption affects shipping lanes. A generic manufacturer whose sole-sourced API comes from a facility under an FDA Import Alert faces an immediate ANDA compliance problem that cannot be resolved without a prior approval supplement to add an alternate API source, a process that typically takes 18-24 months.<\/p>\n\n\n\n

Dual-sourcing strategies for critical APIs require parallel qualification programs, analytical method transfer validation, and comparative dissolution studies to verify that APIs from different manufacturers produce equivalent finished-dose performance. The investment is real, but the supply chain optionality it creates is a direct risk mitigation against both regulatory and geopolitical supply disruption. Some large generic manufacturers, including Teva Pharmaceutical Industries and Viatris (which inherited the Mylan API vertical integration assets), have maintained partial backward integration into API manufacturing as a structural hedge against sourcing risk.<\/p>\n\n\n\n

Blockchain and Supply Chain Traceability<\/strong><\/h3>\n\n\n\n

The Drug Supply Chain Security Act (DSCSA), which reached its full serialization and track-and-trace implementation requirements in November 2024, mandates that trading partners exchange product tracing information at the package level using an interoperable electronic system. Compliance with DSCSA is distinct from QMS supplier qualification, but the data infrastructure they require overlaps significantly.<\/p>\n\n\n\n

Blockchain-based traceability systems, which provide an immutable, distributed ledger of custody transfers, offer a technical architecture that satisfies DSCSA’s interoperability requirements while extending visibility deeper into the supply chain than the statute requires. For a generic manufacturer, real-time API batch traceability from synthesis through compounding, granulation, compression, and packaging to distribution creates the audit trail that supports both DSCSA compliance and QMS deviation investigation. When a finished-product recall requires rapid lot tracing, a blockchain-based system can identify affected lots in hours rather than days, containing the scope of the recall and reducing its financial impact.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

Supplier qualification is the most variable element of a generic manufacturer’s QMS risk profile. Manufacturers that qualify suppliers once and audit infrequently accumulate latent quality risk that surfaces at the worst possible moment, typically when a CRL has already delayed a product launch and the manufacturer’s financial position makes remediation expensive. A supplier qualification program designed to detect quality trend deterioration before it produces a lot rejection, through real-time CoA analytics and statistical supplier performance monitoring, converts supplier risk from a reactive to a proactive management problem.<\/p>\n\n\n\n

Investment Strategy<\/strong><\/p>\n\n\n\n

Acquirers of generic manufacturers should conduct granular API supplier mapping as part of due diligence. The critical metrics are: the number of sole-sourced critical APIs, the geographic concentration of the API supply base, the frequency and findings of recent supplier audits, and the manufacturer’s DSCSA compliance status. A manufacturer with two or more sole-sourced APIs from facilities under active FDA enforcement actions or with unresolved Import Alerts represents a material supply disruption risk that warrants significant purchase price adjustment or an escrow provision tied to alternate supplier qualification milestones.<\/p>\n\n\n\n

\n\n\n\n

Laboratory Controls, Data Integrity, and 21 CFR Part 11<\/strong><\/h2>\n\n\n\n

Out-of-Specification Investigations Under 21 CFR 211.192<\/strong><\/h3>\n\n\n\n

Out-of-specification (OOS) results are the most consequential laboratory event in a generic drug QMS. FDA’s 2006 guidance on investigating OOS results, which derives from the Barr Laboratories consent decree and the subsequent court ruling in United States v. Barr Laboratories, Inc., establishes a two-phase investigation framework: Phase I is a laboratory investigation to determine whether the OOS result was caused by a laboratory error; Phase II is a full-scale manufacturing investigation if no laboratory error is identified.<\/p>\n\n\n\n

The Barr ruling established that an invalidated OOS result must have a scientifically defensible, documented, and prospectively defined justification. Retesting a sample without documented Phase I laboratory error confirmation, and then averaging the passing and failing results, was specifically prohibited. This standard has not changed, but Warning Letter observations for inadequate OOS investigations remain among FDA’s most frequently cited laboratory control deficiencies, suggesting that the organizational knowledge of the Barr standard is imperfect across the industry.<\/p>\n\n\n\n

Phase II manufacturing investigations must address the full scope of the OOS result: all batches of the affected product manufactured in the same time window, all materials from the same lot used in those batches, and any other products that share the suspect process or raw material. A narrow manufacturing investigation that fails to extend to potentially affected related batches generates a 483 observation almost automatically.<\/p>\n\n\n\n

Data Integrity: the 21 CFR Part 11 Compliance Architecture<\/strong><\/h3>\n\n\n\n

FDA’s focus on data integrity in generic drug manufacturing intensified dramatically after a series of high-profile enforcement actions against Indian API manufacturers, including Sun Pharmaceutical Industries’ Halol facility (which received an import alert in 2014 after repeat inspection failures), Ranbaxy Laboratories (which pleaded guilty to felony charges in 2013 related to data fraud across multiple facilities), and Wockhardt’s Waluj facility. These cases established that data integrity failures are not technical Part 11 violations; they are fraud, subject to criminal prosecution.<\/p>\n\n\n\n

The current data integrity framework derives from FDA’s 2018 guidance, ‘Data Integrity and Compliance With Drug CGMP,’ which applies the ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available) to all GMP data regardless of whether it is paper or electronic. For a generic manufacturer’s laboratory, ALCOA+ compliance requires that every analytical result, including raw chromatography data, instrument logs, environmental monitoring records, and stability data, is generated and stored in systems where audit trails are active, access is role-based, and no user has the ability to delete records without generating a traceable audit trail entry.<\/p>\n\n\n\n

The most common data integrity vulnerabilities in generic drug manufacturing laboratories are: shared login credentials that prevent individual attributability; test-until-pass practices where samples are reinjected without documented Phase I OOS investigation; and the use of standalone laboratory computers disconnected from the site’s networked LIMS, which allows local audit trail manipulation. Remediation of a site with documented data integrity problems requires a comprehensive retrospective data review, often supervised by a third-party expert, and represents one of the most resource-intensive and reputationally damaging QMS failures a manufacturer can experience.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

Data integrity is binary in FDA’s enforcement posture. A single documented instance of data manipulation triggers a site-wide audit and, depending on severity and scope, an Import Alert. The organizational behavior patterns that produce data integrity failures, pressure to pass results, lack of consequences for manipulation, and management that does not review audit trails, are quality culture failures that the QMM program is specifically designed to identify before FDA does.<\/p>\n\n\n\n

\n\n\n\n

The QMS as an IP Asset: Documentation, Trade Secrets, and Freedom-to-Operate<\/strong><\/h2>\n\n\n\n

Manufacturing Know-How as Protectable IP<\/strong><\/h3>\n\n\n\n

The intersection of QMS documentation and intellectual property is one of the least discussed but most commercially significant aspects of generic drug manufacturing. A generic manufacturer’s QMS generates continuous records of process characterization data, DoE results, formulation optimization studies, and manufacturing process innovations. That body of data constitutes manufacturing know-how that may be protectable as a trade secret under the Defend Trade Secrets Act (DTSA) or, where novel and non-obvious, as a method-of-manufacture patent.<\/p>\n\n\n\n

The trade secret option does not require registration and takes effect immediately, but it requires that the manufacturer take reasonable steps to maintain secrecy, which means that QMS documents containing protectable know-how must be clearly marked as confidential, access-controlled within the eDMS, and excluded from vendor audit reports and regulatory submissions where possible. The tension between the FDA’s expectation of documentary transparency in inspections and the manufacturer’s interest in protecting manufacturing know-how is real, and requires legal-QMS coordination to manage.<\/p>\n\n\n\n

The patent option for process improvements requires novelty, non-obviousness, and utility. For a generic drug manufacturer, the most common patentable manufacturing innovations are: novel crystal forms or particle size distributions of an API that improve bioequivalence performance, novel co-processing techniques for excipients that improve blend uniformity or tablet compressibility, novel in-process control strategies, and novel continuous manufacturing configurations. A manufacturer that files a method-of-manufacture patent on a process that produces superior dissolution characteristics for a generic equivalent of a branded drug has created a manufacturing cost moat that competitors filing ANDAs for the same RLD cannot easily replicate.<\/p>\n\n\n\n

ANDA Filing Strategy and the Orange Book<\/strong><\/h3>\n\n\n\n

The Hatch-Waxman Act created the ANDA pathway specifically to allow generic manufacturers to file abbreviated applications that rely on the innovator’s safety and efficacy data. The patent certification requirement, specifically the Paragraph IV certification that asserts the innovator’s listed patent is invalid, unenforceable, or not infringed by the generic product, is the mechanism by which the 180-day exclusivity clock starts for the first filer.<\/p>\n\n\n\n

The QMS documentation of a generic manufacturer’s bioequivalence studies, process characterization work, and formulation development constitutes the scientific record that supports both the ANDA and any subsequent Paragraph IV litigation. A QMS that generates clean, complete, and audit-trailable BE study documentation, including all raw data, investigator correspondence, and protocol deviations, produces a litigation-ready record that is materially harder for the innovator to challenge than a study record with missing audit trails or unexplained result anomalies.<\/p>\n\n\n\n

Innovator companies file citizen petitions under 21 CFR 10.30 to delay generic approval by raising manufacturing or formulation questions that require FDA response before ANDA approval. A generic manufacturer whose CMC documentation is thorough and whose QMS is visibly mature has a stronger basis for FDA to deny those petitions on the grounds that the manufacturing concerns raised do not constitute a genuine safety issue.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

The QMS documentation system is simultaneously a regulatory compliance tool, a litigation defense asset, and a potential IP creation mechanism. Generic manufacturers that understand all three dimensions extract substantially more value from their QMS investment than those who treat documentation as a compliance cost.<\/p>\n\n\n\n

Investment Strategy<\/strong><\/p>\n\n\n\n

IP teams evaluating a generic manufacturer’s competitive moat should assess whether the company has filed any method-of-manufacture patents derived from QMS process innovations, whether it has documented trade secret designation protocols for proprietary process parameters, and whether its ANDA CMC documentation is structured to withstand Paragraph IV litigation scrutiny. A manufacturer with two or more defensible manufacturing process patents in high-volume generic categories holds a cost-position advantage that generates compounding returns as competitors attempt to replicate its process economics.<\/p>\n\n\n\n

\n\n\n\n

Continuous Process Verification and Annual Product Reviews<\/strong><\/h2>\n\n\n\n

Stage 3 Validation: CPV Under FDA’s 2011 Process Validation Guidance<\/strong><\/h3>\n\n\n\n

FDA’s 2011 process validation guidance replaced the traditional three-batch validation model with a lifecycle approach that aligns with ICH Q10. Stage 3, Continued Process Verification (CPV), requires that manufacturers collect and analyze data on a statistical basis to ensure the process remains in a state of control during routine commercial production. This is not a one-time assessment but an ongoing program that runs throughout the product’s commercial life.<\/p>\n\n\n\n

CPV programs use control charts, capability indices, and alert and action limits to detect process drift before it produces OOS results. For a high-volume generic solid oral, the CPV program typically monitors batch-level statistics for assay, dissolution, hardness, and content uniformity, with trend alerts triggering investigation when running means or standard deviations approach action limits. The Cpk target, the process capability index that measures how centered and tight a process is within specification limits, is typically set at a minimum of 1.33 for a process considered capable, with 1.67 as the target for critical CQAs with tight specification windows.<\/p>\n\n\n\n

Statistical process control (SPC) tools appropriate for CPV include Western Electric rules for control chart interpretation (which flag non-random patterns including eight consecutive points on one side of the mean, two of three points beyond two sigma, and four of five points beyond one sigma), exponentially weighted moving average (EWMA) charts for detecting small sustained shifts in a process mean, and multivariate statistical process control (MSPC) for processes with multiple interdependent CQAs.<\/p>\n\n\n\n

Annual Product Reviews: Converting Data into Decisions<\/strong><\/h3>\n\n\n\n

21 CFR 211.180(e) requires annual product reviews for each drug product, covering a representative number of batches (at a minimum, the first three batches and then a representative sample each year) to determine whether specifications remain appropriate, identify any adverse or favorable trend, and determine whether the product and manufacturing process should be requalified. FDA investigators review APR documentation to assess whether the manufacturer is actually using quality data to drive manufacturing decisions or simply generating documents that satisfy the requirement without informing management.<\/p>\n\n\n\n

A high-quality APR converts twelve months of batch data, stability results, complaint trends, return and rejection data, CAPA completion status, and supplier performance metrics into a decision-ready report that directly informs product strategy. If the APR shows specification drift that correlates with a change in an API supplier’s particle size distribution, the QMS should trace that signal through to a CAPA that addresses the supplier specification. If it shows complaint rates increasing in a specific market, the APR should drive a root cause analysis of whether the issue is manufacturing, distribution, or product design-related.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

CPV and APR programs are the operational expression of ICH Q10’s continuous improvement mandate. Manufacturers that treat them as documentation exercises rather than decision-support systems miss the most valuable output of their QMS investment: the ability to detect and correct quality trends before they generate regulatory events, batch failures, or product recalls.<\/p>\n\n\n\n

\n\n\n\n

Technology Infrastructure: Digital QMS, AI-Driven Analytics, and the Future State<\/strong><\/h2>\n\n\n\n

Enterprise QMS Platforms and Validated Software<\/strong><\/h3>\n\n\n\n

The market for pharmaceutical quality management software, which includes companies such as Veeva Systems (Vault QualityDocs and Vault QMS), MasterControl, Sparta Systems (TrackWise Digital), and Ideagen (Q-Pulse), has consolidated around cloud-based SaaS platforms that provide integrated document control, CAPA management, deviation management, change control, and audit management in a single validated environment. For a mid-size generic manufacturer, migrating from a legacy paper or hybrid system to an integrated eDMS\/eQMS platform typically requires 12-24 months of validated implementation, including process redesign, data migration, and user acceptance testing.<\/p>\n\n\n\n

The validation framework for a cloud-based eQMS follows GAMP 5 Category 4 (configurable software), which requires validation documentation covering installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ), but allows risk-based reduction of test scripts for low-criticality functionalities. The vendor’s regulatory support package, including their own qualification documentation, infrastructure qualification for their cloud environment, and 21 CFR Part 11 compliance matrix, forms the foundation of the manufacturer’s validation package.<\/p>\n\n\n\n

AI-Driven Predictive Quality Analytics<\/strong><\/h3>\n\n\n\n

The application of machine learning to pharmaceutical manufacturing quality data is moving from proof-of-concept to production deployment across the largest generic manufacturers. The highest-value applications are: predictive OOS detection, where ML models trained on historical batch process data identify batches with elevated OOS probability before end-product testing is complete; anomaly detection in environmental monitoring data for sterile manufacturing facilities; and supplier quality trend prediction, where ML models trained on incoming material test data and supplier audit findings forecast supplier quality failures before they affect production.<\/p>\n\n\n\n

FDA’s 2025 generative AI pilot for internal reviewers signals that the agency is actively developing its own AI-assisted review capabilities. Manufacturers that adopt AI-driven quality analytics before their competitors create a data quality and process insight advantage that compounds over time: the more historical process data a manufacturer holds in clean, audit-trailable format, the more predictive its models become, and the lower its defect detection lag.<\/p>\n\n\n\n

The data governance requirement for AI-driven quality analytics is identical to the Part 11 requirement for any other GMP data: the data used to train models must be attributable, accurate, complete, and audit-trailable. A model trained on incomplete or manipulated historical data will produce incorrect predictions, which in a quality context means false negatives, missed OOS signals, that are more dangerous than no model at all.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

The technology investment required to build a digital, AI-enabled QMS is substantial, but the structural alternative is a labor-intensive, reactive quality system that cannot scale as product portfolios grow. For a generic manufacturer with 50 or more active ANDAs across multiple dosage forms, manual quality data management is not a sustainable model. The manufacturers that treat QMS technology as infrastructure rather than overhead will have a systematic process quality advantage within five years.<\/p>\n\n\n\n

\n\n\n\n

Building a Quality Culture: Training, Management Review, and the QMM Five Practice Areas<\/strong><\/h2>\n\n\n\n

Management Review: Converting Quality Data into Executive Action<\/strong><\/h3>\n\n\n\n

ICH Q10 requires that senior management review the pharmaceutical quality system at defined intervals to ensure its continued suitability, adequacy, and effectiveness. The management review is not a documentation exercise; it is the mechanism by which quality data reaches the executive level and drives resource allocation. An effective management review presents: process capability trends across the product portfolio, CAPA effectiveness and aging data, supplier quality performance versus targets, internal audit findings and closure status, regulatory inspection outcomes, product complaint rates and trends, and a forward-looking risk assessment of the quality pipeline.<\/p>\n\n\n\n

The QMM program’s first practice area, management commitment to quality, scored highest in the 2024 pilot cohort. But the assessment revealed a nuanced picture: management commitment expressed as quality policy statements and resource provision scored well, while management commitment expressed as the ability to connect quality data to specific manufacturing decisions scored less well. The gap reflects a common organizational pattern where quality is treated as a function rather than a discipline embedded in operations.<\/p>\n\n\n\n

Training Programs: GMP, QbD, and Technical Excellence<\/strong><\/h3>\n\n\n\n

Annual GMP training is a regulatory requirement under 21 CFR 211.68 and 211.192, but compliance-oriented training alone does not produce the technical excellence that the QMM program requires. Technical excellence, as defined in the QMM rubric, encompasses effective data management, understanding of process capabilities and limitations, investment in learning, and adoption of new technical skills including novel manufacturing technologies.<\/p>\n\n\n\n

A training program that builds technical excellence requires role-specific curriculum design: quality control analysts need statistical methods training (SPC, sampling plans, method validation), manufacturing operators need process parameter interpretation and CPP monitoring training, and quality assurance professionals need risk management, CAPA methodology, and regulatory change management training. The training program itself must be validated, with effectiveness checks that go beyond quiz scores to assess behavioral change in quality-relevant job performance.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

Quality culture is the factor that FDA’s QMM program is ultimately designed to assess, because quality culture determines whether a QMS functions as designed or degrades under production pressure. The organizations that score highest in the QMM rubric are those where quality personnel have organizational authority to stop production without escalation, where management review meetings produce resource decisions rather than acceptance of the status quo, and where process engineers and quality scientists collaborate on the same data rather than managing separate reporting streams.<\/p>\n\n\n\n

\n\n\n\n

Addressing Sector-Specific Challenges: Sterile Injectables, Narrow Therapeutic Index Drugs, and Complex Dosage Forms<\/strong><\/h2>\n\n\n\n

Sterile Injectable Manufacturing: The Highest-Risk Category<\/strong><\/h3>\n\n\n\n

Sterile injectables represent the highest regulatory risk category in generic drug manufacturing, and account for a disproportionate share of drug shortages. IQVIA’s 2024 shortage analysis found that 75% of drug shortages involving unlaunched generics were injectable products. The manufacturing complexity of sterile injectables, which require validated aseptic processing or terminal sterilization, environmental monitoring programs under 21 CFR Annex 1 (the EU standard that FDA increasingly references), and container closure integrity testing, creates barriers to entry and barriers to quality remediation that oral solid manufacturers do not face.<\/p>\n\n\n\n

FDA’s 2023 Aseptic Processing guidance, which aligns more closely with EU GMP Annex 1 (revised 2022), introduced contamination control strategy (CCS) as a required element of sterile manufacturing QMS documentation. A CCS is a holistic, facility-wide document that describes how environmental contamination risks are identified, assessed, controlled, and monitored. It integrates HVAC design qualification data, cleanroom gowning and behavior controls, equipment sterilization validation, and environmental monitoring alert and action limits into a single risk-based narrative. Sterile manufacturers that have not developed a CCS aligned with the 2023 guidance face a 483 observation in the next routine inspection.<\/p>\n\n\n\n

Narrow Therapeutic Index Drugs: Bioequivalence and QMM Intersection<\/strong><\/h3>\n\n\n\n

Narrow therapeutic index (NTI) drugs, including warfarin, digoxin, lithium, phenytoin, carbamazepine, and levothyroxine, require tighter bioequivalence criteria than standard products. FDA’s regulations for NTI drugs under 21 CFR 320.33 allow the agency to require a scaled average bioequivalence (SABE) approach that narrows the 80-125% BE window based on the within-subject variability of the reference product. For generic manufacturers, this tighter window requires more precise manufacturing process control than standard generics, which directly elevates the CPP and CMA control requirements in the QMS.<\/p>\n\n\n\n

The QMS documentation burden for an NTI drug product is correspondingly higher than for standard products: specification tightening, enhanced dissolution testing at multiple pH values, stability commitment to demonstrate shelf-life consistency, and a post-approval stability program that monitors for any dissolution or assay trend that might affect bioequivalence. Manufacturers that have successfully built QMS infrastructure for NTI products possess a quality control capability that transfers readily to complex generics and biosimilar drug-device combinations.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n

The technical demands of sterile injectable and NTI drug manufacturing reward manufacturers that have invested in QMS infrastructure that exceeds minimum cGMP requirements. The market entry barriers created by these technical demands also generate more durable competitive positions for manufacturers that hold ANDAs in these categories. The QMM program’s emphasis on technical excellence maps directly onto the capabilities that sterile and NTI manufacturing requires.<\/p>\n\n\n\n

\n\n\n\n

The Consolidated Investment Framework: QMS Maturity as Competitive Strategy<\/strong><\/h2>\n\n\n\n

A generic drug manufacturer’s QMS is not a regulatory overhead item. It is the operational infrastructure on which every commercial outcome depends: ANDA approval timing, batch failure rates, recall exposure, inspection outcomes, drug shortage risk, and the ability to launch new products without remediation delays.<\/p>\n\n\n\n

The QMM program’s evolution from voluntary pilot to anticipated rating system will within the next several years make quality maturity publicly legible in a way it has never been before. GPOs and hospital systems that currently procure generics primarily on price will have a quality-differentiated procurement framework. Federal emergency stockpile programs will preferentially award contracts to QMM-rated facilities. ANDA review prioritization in shortage categories, which FDA already practices informally, may be formally linked to QMM standing.<\/p>\n\n\n\n

The manufacturers that begin building QMM-aligned capability now, specifically in the technical excellence and advanced quality system practice areas where the 2024 pilot cohort scored below expectation, will reach a mature state by the time ratings matter competitively. Those that wait until the rating system is formalized will spend the next regulatory cycle catching up.<\/p>\n\n\n\n

The financial case is concrete. CRL avoidance, batch failure reduction, CAPA cycle time compression, and post-approval change management through lower-burden regulatory pathways each carry measurable dollar values. A generic manufacturer with 30 active ANDAs and a 15% CRL rate on new filings that reduces that rate to 8% through QbD-driven CMC development recovers millions in delayed launch revenue annually. A sterile injectable manufacturer that reduces its OOS investigation cycle time from 90 days to 30 days reduces work-in-process hold inventory, freeing working capital. The QMS investment case does not require intangible quality culture arguments. The numbers close on regulatory efficiency alone.<\/p>\n\n\n\n

\n\n\n\n

Sources: FDA CDER QMM Program documentation (2024-2026); ICH Q8(R2), Q9(R1), Q10, Q12; FDA Guidance on Process Validation (2011); FDA Guidance on Data Integrity and Compliance with Drug CGMP (2018); IQVIA Institute, ‘Trends in Drug Shortages and ANDA Approvals in the U.S.’ (2024); HHS ASPE, ‘Analysis of Drug Shortages, 2018-2023’ (2025); RAPS QMM pilot coverage (2024-2025); PMC4070262, Yu et al., ‘Understanding Pharmaceutical Quality by Design,’ AAPS Journal (2014); PharmExec QMM program analysis (April 2026); Arnold & Porter QMM advisory (February 2026).<\/em><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Quality failures in generic drug manufacturing are not a compliance inconvenience. They are a market-exit event. Between 2022 and 2024, […]<\/p>\n","protected":false},"author":1,"featured_media":38426,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-32782","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=32782"}],"version-history":[{"count":4,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32782\/revisions"}],"predecessor-version":[{"id":38427,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32782\/revisions\/38427"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38426"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=32782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=32782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=32782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}